Comparing of SeaSpine Holdings Corporation (SPNE) and Intersect ENT Inc. (NASDAQ:XENT)

Both SeaSpine Holdings Corporation (NASDAQ:SPNE) and Intersect ENT Inc. (NASDAQ:XENT) are each other’s competitor in the Medical Appliances & Equipment industry. Thus the compare of their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SeaSpine Holdings Corporation 143.44M 1.94 33.52M -4.15 0.00
Intersect ENT Inc. 108.47M 9.65 22.92M -0.76 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of SeaSpine Holdings Corporation and Intersect ENT Inc.

Profitability

Table 2 provides us SeaSpine Holdings Corporation and Intersect ENT Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
SeaSpine Holdings Corporation -23.37% -28.8% -22%
Intersect ENT Inc. -21.13% -14.8% -13.1%

Risk & Volatility

SeaSpine Holdings Corporation’s current beta is 0.04 and it happens to be 96.00% less volatile than Standard & Poor’s 500. Intersect ENT Inc.’s 32.00% less volatile than Standard & Poor’s 500 which is a result of the 0.68 beta.

Liquidity

The Current Ratio and a Quick Ratio of SeaSpine Holdings Corporation are 2.9 and 1.3. Competitively, Intersect ENT Inc. has 7.5 and 6.9 for Current and Quick Ratio. Intersect ENT Inc.’s better ability to pay short and long-term obligations than SeaSpine Holdings Corporation.

Analyst Recommendations

Recommendations and Ratings for SeaSpine Holdings Corporation and Intersect ENT Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
SeaSpine Holdings Corporation 0 0 2 3.00
Intersect ENT Inc. 0 0 2 3.00

SeaSpine Holdings Corporation has a 48.95% upside potential and an average target price of $22. On the other hand, Intersect ENT Inc.’s potential upside is 10.36% and its consensus target price is $37.5. The data provided earlier shows that SeaSpine Holdings Corporation appears more favorable than Intersect ENT Inc., based on analyst opinion.

Insider and Institutional Ownership

Institutional investors owned 61.5% of SeaSpine Holdings Corporation shares and 0% of Intersect ENT Inc. shares. 3.1% are SeaSpine Holdings Corporation’s share owned by insiders. Comparatively, Intersect ENT Inc. has 2.1% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
SeaSpine Holdings Corporation -16.21% -5.36% -17.69% -1.9% 42.14% -20.67%
Intersect ENT Inc. -1.97% 14.16% 12.49% 16.79% -5.65% 20.19%

For the past year SeaSpine Holdings Corporation had bearish trend while Intersect ENT Inc. had bullish trend.

Summary

Intersect ENT Inc. beats on 9 of the 11 factors SeaSpine Holdings Corporation.

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and Internationally. The company provides orthobiologics and spinal fusion hardware solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers its orthobiologics products in various forms, such as putties, pastes, and strips. Its spinal fusion hardware products comprise products for spinal fusion in minimally invasive surgery, complex spine, deformity, and degenerative procedures throughout the lumbar, thoracic, and cervical regions of the spine. The company was incorporated in 2015 and is headquartered in Carlsbad, California.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.